aluates Reports

$ 0.0

Automative

Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-18O20079

BUY CHAPTERS

Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Research Report 2025

Code: QYRE-Auto-18O20079

Report

November 2025

Pages:105

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Self-administered Biologics for Metabolic & Endocrine Disorders Market Size

The global market for Self-administered Biologics for Metabolic & Endocrine Disorders was valued at US$ 68512 million in the year 2024 and is projected to reach a revised size of US$ 95096 million by 2031, growing at a CAGR of 4.9% during the forecast period.

Self-administered Biologics for Metabolic & Endocrine Disorders Market

Self-administered biologics for metabolic and endocrine disorders refer to biologic therapies that patients can administer independently at home or outside healthcare facilities. These drugs are primarily used for chronic management of diabetes, obesity, thyroid disorders, bone metabolism diseases, and growth hormone deficiencies. They combine advanced biologic molecules—such as recombinant proteins, monoclonal antibodies, and GLP-1 receptor agonists—with user-friendly delivery systems, including prefilled pens, autoinjectors, microneedle patches, and wearable pumps. The field’s rapid evolution is driven by progress in biologic molecule stabilization and device innovation, representing a shift in metabolic and endocrine disease management toward patient-centric, intelligent, and personalized therapeutics.The average gross profit margin of this product is 60%.

The increasing global prevalence of metabolic and endocrine disorders serves as the fundamental driver of market expansion for self-administered biologics. The widespread adoption of long-term biologic therapies for diabetes and obesity, coupled with rising patient demand for convenient and safe home-based treatments, is reshaping therapeutic paradigms. Technological advances in smart and wearable injection systems enable drug-device integration, enhancing adherence and clinical outcomes. Meanwhile, the healthcare shift from institutional to community-based care further accelerates adoption of self-administration models.

The market still faces significant technical and operational challenges, including biologic molecule stability, storage sensitivity, and pharmacokinetic control. Patient adherence and proper self-administration training remain major concerns, particularly for complex formulations such as long-acting GLP-1 agonists or fusion proteins. High production costs, stringent cold-chain logistics, and incomplete reimbursement frameworks in emerging regions also hinder market penetration. Additionally, divergent regulatory pathways for biologic-drug combination products across countries increase commercialization uncertainty.

The downstream demand is shifting from physician-centered administration to patient-centered experience. Self-administered biologics are expanding rapidly in diabetes and obesity management, with GLP-1 analogs, insulin analogs, and recombinant human growth hormones emerging as dominant categories. Patients increasingly prefer smart injection devices and patches with automatic needle concealment, single-use safety, and lock features. Furthermore, integration of digital health and remote monitoring technologies is transforming these systems into data-enabled therapeutic platforms for tracking adherence and optimizing dosing.Key upstream materials for self-administered biologics include high-purity protein actives, stabilizing excipients such as polysaccharides and buffered systems, medical-grade polymers (e.g., polypropylene, polycarbonate, and TPE elastomers), and high-performance injection components. The purification and lyophilization processes of biologic actives determine drug stability, while the biocompatibility and barrier properties of packaging materials influence preservation and delivery efficiency. With the rise of wearable and microneedle systems, microfluidic components, flexible electrode materials, and aseptic coating technologies have become crucial elements of upstream innovation.

This report aims to provide a comprehensive presentation of the global market for Self-administered Biologics for Metabolic & Endocrine Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Self-administered Biologics for Metabolic & Endocrine Disorders.

The Self-administered Biologics for Metabolic & Endocrine Disorders market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Self-administered Biologics for Metabolic & Endocrine Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, by Delivery Device and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Self-administered Biologics for Metabolic & Endocrine Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Self-administered Biologics for Metabolic & Endocrine Disorders Market Report

Report Metric	Details
Report Name	Self-administered Biologics for Metabolic & Endocrine Disorders Market
Accounted market size in year	US$ 68512 million
Forecasted market size in 2031	US$ 95096 million
CAGR	4.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Insulin GLP-1 Receptor Agonists rhGH Other
Segment by Delivery Device	Pre-filled syringe pens Auto-injectors Wearable infusion devices Others
Segment by Technological Characteristics	Conventional Liquid Formulations Sustained/Extended-release Biologics Lyophilized Ready-to-use Formulations
Segment by Application	Hospital Home-based Self-administration Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk, Sanofi-Aventis, Eli Lilly, Tonghua Dongbao, United Laboratory, Biocon, GSK, Bristol-Myers Squibb, Ganlee, Julphar Diabetes, Wockhardt, Pfizer, Merck Serono, Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Amoytop, Anhui Anke Biotechnology, Changchun High-tech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Delivery Device etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Self-administered Biologics for Metabolic & Endocrine Disorders company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Self-administered Biologics for Metabolic & Endocrine Disorders Market growing?

Ans: The Self-administered Biologics for Metabolic & Endocrine Disorders Market witnessing a CAGR of 4.9% during the forecast period 2025-2031.

What is the Self-administered Biologics for Metabolic & Endocrine Disorders Market size in 2031?

Ans: The Self-administered Biologics for Metabolic & Endocrine Disorders Market size in 2031 will be US$ 95096 million.

Who are the main players in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report?

Ans: The main players in the Self-administered Biologics for Metabolic & Endocrine Disorders Market are Novo Nordisk, Sanofi-Aventis, Eli Lilly, Tonghua Dongbao, United Laboratory, Biocon, GSK, Bristol-Myers Squibb, Ganlee, Julphar Diabetes, Wockhardt, Pfizer, Merck Serono, Roche, Ferring Pharmaceuticals, GeneScience Pharmaceuticals, Ipsen, LG Life Sciences, Amoytop, Anhui Anke Biotechnology, Changchun High-tech

What are the Application segmentation covered in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report?

Ans: The Applications covered in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report are Hospital, Home-based Self-administration, Other

What are the Type segmentation covered in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report?

Ans: The Types covered in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report are Insulin, GLP-1 Receptor Agonists, rhGH, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Insulin

1.2.3 GLP-1 Receptor Agonists

1.2.4 rhGH

1.2.5 Other

1.3 Market by Delivery Device

1.3.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Delivery Device: 2020 VS 2024 VS 2031

1.3.2 Pre-filled syringe pens

1.3.3 Auto-injectors

1.3.4 Wearable infusion devices

1.3.5 Others

1.4 Market by Technological Characteristics

1.4.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Technological Characteristics: 2020 VS 2024 VS 2031

1.4.2 Conventional Liquid Formulations

1.4.3 Sustained/Extended-release Biologics

1.4.4 Lyophilized Ready-to-use Formulations

1.5 Market by Application

1.5.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Growth by Application: 2020 VS 2024 VS 2031

1.5.2 Hospital

1.5.3 Home-based Self-administration

1.5.4 Other

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Perspective (2020-2031)

2.2 Global Self-administered Biologics for Metabolic & Endocrine Disorders Growth Trends by Region

2.2.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Self-administered Biologics for Metabolic & Endocrine Disorders Historic Market Size by Region (2020-2025)

2.2.3 Self-administered Biologics for Metabolic & Endocrine Disorders Forecasted Market Size by Region (2026-2031)

2.3 Self-administered Biologics for Metabolic & Endocrine Disorders Market Dynamics

2.3.1 Self-administered Biologics for Metabolic & Endocrine Disorders Industry Trends

2.3.2 Self-administered Biologics for Metabolic & Endocrine Disorders Market Drivers

2.3.3 Self-administered Biologics for Metabolic & Endocrine Disorders Market Challenges

2.3.4 Self-administered Biologics for Metabolic & Endocrine Disorders Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Self-administered Biologics for Metabolic & Endocrine Disorders Players by Revenue

3.1.1 Global Top Self-administered Biologics for Metabolic & Endocrine Disorders Players by Revenue (2020-2025)

3.1.2 Global Self-administered Biologics for Metabolic & Endocrine Disorders Revenue Market Share by Players (2020-2025)

3.2 Global Top Self-administered Biologics for Metabolic & Endocrine Disorders Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Self-administered Biologics for Metabolic & Endocrine Disorders Revenue

3.4 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Concentration Ratio

3.4.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Self-administered Biologics for Metabolic & Endocrine Disorders Revenue in 2024

3.5 Global Key Players of Self-administered Biologics for Metabolic & Endocrine Disorders Head office and Area Served

3.6 Global Key Players of Self-administered Biologics for Metabolic & Endocrine Disorders, Product and Application

3.7 Global Key Players of Self-administered Biologics for Metabolic & Endocrine Disorders, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Self-administered Biologics for Metabolic & Endocrine Disorders Breakdown Data by Type

4.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Historic Market Size by Type (2020-2025)

4.2 Global Self-administered Biologics for Metabolic & Endocrine Disorders Forecasted Market Size by Type (2026-2031)

5 Self-administered Biologics for Metabolic & Endocrine Disorders Breakdown Data by Application

5.1 Global Self-administered Biologics for Metabolic & Endocrine Disorders Historic Market Size by Application (2020-2025)

5.2 Global Self-administered Biologics for Metabolic & Endocrine Disorders Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size (2020-2031)

6.2 North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025)

6.4 North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Size (2020-2031)

7.2 Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025)

7.4 Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Size (2020-2031)

8.2 Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Region (2020-2025)

8.4 Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size (2020-2031)

9.2 Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025)

9.4 Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Size (2020-2031)

10.2 Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025)

10.4 Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novo Nordisk

11.1.1 Novo Nordisk Company Details

11.1.2 Novo Nordisk Business Overview

11.1.3 Novo Nordisk Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.1.4 Novo Nordisk Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.1.5 Novo Nordisk Recent Development

11.2 Sanofi-Aventis

11.2.1 Sanofi-Aventis Company Details

11.2.2 Sanofi-Aventis Business Overview

11.2.3 Sanofi-Aventis Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.2.4 Sanofi-Aventis Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.2.5 Sanofi-Aventis Recent Development

11.3 Eli Lilly

11.3.1 Eli Lilly Company Details

11.3.2 Eli Lilly Business Overview

11.3.3 Eli Lilly Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.3.4 Eli Lilly Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.3.5 Eli Lilly Recent Development

11.4 Tonghua Dongbao

11.4.1 Tonghua Dongbao Company Details

11.4.2 Tonghua Dongbao Business Overview

11.4.3 Tonghua Dongbao Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.4.4 Tonghua Dongbao Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.4.5 Tonghua Dongbao Recent Development

11.5 United Laboratory

11.5.1 United Laboratory Company Details

11.5.2 United Laboratory Business Overview

11.5.3 United Laboratory Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.5.4 United Laboratory Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.5.5 United Laboratory Recent Development

11.6 Biocon

11.6.1 Biocon Company Details

11.6.2 Biocon Business Overview

11.6.3 Biocon Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.6.4 Biocon Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.6.5 Biocon Recent Development

11.7 GSK

11.7.1 GSK Company Details

11.7.2 GSK Business Overview

11.7.3 GSK Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.7.4 GSK Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.7.5 GSK Recent Development

11.8 Bristol-Myers Squibb

11.8.1 Bristol-Myers Squibb Company Details

11.8.2 Bristol-Myers Squibb Business Overview

11.8.3 Bristol-Myers Squibb Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.8.4 Bristol-Myers Squibb Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.8.5 Bristol-Myers Squibb Recent Development

11.9 Ganlee

11.9.1 Ganlee Company Details

11.9.2 Ganlee Business Overview

11.9.3 Ganlee Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.9.4 Ganlee Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.9.5 Ganlee Recent Development

11.10 Julphar Diabetes

11.10.1 Julphar Diabetes Company Details

11.10.2 Julphar Diabetes Business Overview

11.10.3 Julphar Diabetes Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.10.4 Julphar Diabetes Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.10.5 Julphar Diabetes Recent Development

11.11 Wockhardt

11.11.1 Wockhardt Company Details

11.11.2 Wockhardt Business Overview

11.11.3 Wockhardt Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.11.4 Wockhardt Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.11.5 Wockhardt Recent Development

11.12 Pfizer

11.12.1 Pfizer Company Details

11.12.2 Pfizer Business Overview

11.12.3 Pfizer Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.12.4 Pfizer Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.12.5 Pfizer Recent Development

11.13 Merck Serono

11.13.1 Merck Serono Company Details

11.13.2 Merck Serono Business Overview

11.13.3 Merck Serono Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.13.4 Merck Serono Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.13.5 Merck Serono Recent Development

11.14 Roche

11.14.1 Roche Company Details

11.14.2 Roche Business Overview

11.14.3 Roche Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.14.4 Roche Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.14.5 Roche Recent Development

11.15 Ferring Pharmaceuticals

11.15.1 Ferring Pharmaceuticals Company Details

11.15.2 Ferring Pharmaceuticals Business Overview

11.15.3 Ferring Pharmaceuticals Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.15.4 Ferring Pharmaceuticals Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.15.5 Ferring Pharmaceuticals Recent Development

11.16 GeneScience Pharmaceuticals

11.16.1 GeneScience Pharmaceuticals Company Details

11.16.2 GeneScience Pharmaceuticals Business Overview

11.16.3 GeneScience Pharmaceuticals Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.16.4 GeneScience Pharmaceuticals Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.16.5 GeneScience Pharmaceuticals Recent Development

11.17 Ipsen

11.17.1 Ipsen Company Details

11.17.2 Ipsen Business Overview

11.17.3 Ipsen Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.17.4 Ipsen Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.17.5 Ipsen Recent Development

11.18 LG Life Sciences

11.18.1 LG Life Sciences Company Details

11.18.2 LG Life Sciences Business Overview

11.18.3 LG Life Sciences Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.18.4 LG Life Sciences Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.18.5 LG Life Sciences Recent Development

11.19 Amoytop

11.19.1 Amoytop Company Details

11.19.2 Amoytop Business Overview

11.19.3 Amoytop Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.19.4 Amoytop Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.19.5 Amoytop Recent Development

11.20 Anhui Anke Biotechnology

11.20.1 Anhui Anke Biotechnology Company Details

11.20.2 Anhui Anke Biotechnology Business Overview

11.20.3 Anhui Anke Biotechnology Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.20.4 Anhui Anke Biotechnology Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.20.5 Anhui Anke Biotechnology Recent Development

11.21 Changchun High-tech

11.21.1 Changchun High-tech Company Details

11.21.2 Changchun High-tech Business Overview

11.21.3 Changchun High-tech Self-administered Biologics for Metabolic & Endocrine Disorders Introduction

11.21.4 Changchun High-tech Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

11.21.5 Changchun High-tech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Insulin

Table 3. Key Players of GLP-1 Receptor Agonists

Table 4. Key Players of rhGH

Table 5. Key Players of Other

Table 6. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Delivery Device (US$ Million): 2020 VS 2024 VS 2031

Table 7. Key Players of Pre-filled syringe pens

Table 8. Key Players of Auto-injectors

Table 9. Key Players of Wearable infusion devices

Table 10. Key Players of Others

Table 11. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Technological Characteristics (US$ Million): 2020 VS 2024 VS 2031

Table 12. Key Players of Conventional Liquid Formulations

Table 13. Key Players of Sustained/Extended-release Biologics

Table 14. Key Players of Lyophilized Ready-to-use Formulations

Table 15. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 16. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Region (2020-2025) & (US$ Million)

Table 18. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Region (2020-2025)

Table 19. Global Self-administered Biologics for Metabolic & Endocrine Disorders Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 20. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Region (2026-2031)

Table 21. Self-administered Biologics for Metabolic & Endocrine Disorders Market Trends

Table 22. Self-administered Biologics for Metabolic & Endocrine Disorders Market Drivers

Table 23. Self-administered Biologics for Metabolic & Endocrine Disorders Market Challenges

Table 24. Self-administered Biologics for Metabolic & Endocrine Disorders Market Restraints

Table 25. Global Self-administered Biologics for Metabolic & Endocrine Disorders Revenue by Players (2020-2025) & (US$ Million)

Table 26. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Players (2020-2025)

Table 27. Global Top Self-administered Biologics for Metabolic & Endocrine Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders as of 2024)

Table 28. Ranking of Global Top Self-administered Biologics for Metabolic & Endocrine Disorders Companies by Revenue (US$ Million) in 2024

Table 29. Global 5 Largest Players Market Share by Self-administered Biologics for Metabolic & Endocrine Disorders Revenue (CR5 and HHI) & (2020-2025)

Table 30. Global Key Players of Self-administered Biologics for Metabolic & Endocrine Disorders, Headquarters and Area Served

Table 31. Global Key Players of Self-administered Biologics for Metabolic & Endocrine Disorders, Product and Application

Table 32. Global Key Players of Self-administered Biologics for Metabolic & Endocrine Disorders, Date of Enter into This Industry

Table 33. Mergers & Acquisitions, Expansion Plans

Table 34. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Type (2020-2025) & (US$ Million)

Table 35. Global Self-administered Biologics for Metabolic & Endocrine Disorders Revenue Market Share by Type (2020-2025)

Table 36. Global Self-administered Biologics for Metabolic & Endocrine Disorders Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 37. Global Self-administered Biologics for Metabolic & Endocrine Disorders Revenue Market Share by Type (2026-2031)

Table 38. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Application (2020-2025) & (US$ Million)

Table 39. Global Self-administered Biologics for Metabolic & Endocrine Disorders Revenue Market Share by Application (2020-2025)

Table 40. Global Self-administered Biologics for Metabolic & Endocrine Disorders Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 41. Global Self-administered Biologics for Metabolic & Endocrine Disorders Revenue Market Share by Application (2026-2031)

Table 42. North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025) & (US$ Million)

Table 44. North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031) & (US$ Million)

Table 45. Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025) & (US$ Million)

Table 47. Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031) & (US$ Million)

Table 48. Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 49. Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Region (2020-2025) & (US$ Million)

Table 50. Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Region (2026-2031) & (US$ Million)

Table 51. Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 52. Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025) & (US$ Million)

Table 53. Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031) & (US$ Million)

Table 54. Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 55. Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2020-2025) & (US$ Million)

Table 56. Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Country (2026-2031) & (US$ Million)

Table 57. Novo Nordisk Company Details

Table 58. Novo Nordisk Business Overview

Table 59. Novo Nordisk Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 60. Novo Nordisk Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 61. Novo Nordisk Recent Development

Table 62. Sanofi-Aventis Company Details

Table 63. Sanofi-Aventis Business Overview

Table 64. Sanofi-Aventis Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 65. Sanofi-Aventis Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 66. Sanofi-Aventis Recent Development

Table 67. Eli Lilly Company Details

Table 68. Eli Lilly Business Overview

Table 69. Eli Lilly Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 70. Eli Lilly Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 71. Eli Lilly Recent Development

Table 72. Tonghua Dongbao Company Details

Table 73. Tonghua Dongbao Business Overview

Table 74. Tonghua Dongbao Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 75. Tonghua Dongbao Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 76. Tonghua Dongbao Recent Development

Table 77. United Laboratory Company Details

Table 78. United Laboratory Business Overview

Table 79. United Laboratory Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 80. United Laboratory Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 81. United Laboratory Recent Development

Table 82. Biocon Company Details

Table 83. Biocon Business Overview

Table 84. Biocon Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 85. Biocon Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 86. Biocon Recent Development

Table 87. GSK Company Details

Table 88. GSK Business Overview

Table 89. GSK Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 90. GSK Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 91. GSK Recent Development

Table 92. Bristol-Myers Squibb Company Details

Table 93. Bristol-Myers Squibb Business Overview

Table 94. Bristol-Myers Squibb Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 95. Bristol-Myers Squibb Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 96. Bristol-Myers Squibb Recent Development

Table 97. Ganlee Company Details

Table 98. Ganlee Business Overview

Table 99. Ganlee Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 100. Ganlee Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 101. Ganlee Recent Development

Table 102. Julphar Diabetes Company Details

Table 103. Julphar Diabetes Business Overview

Table 104. Julphar Diabetes Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 105. Julphar Diabetes Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 106. Julphar Diabetes Recent Development

Table 107. Wockhardt Company Details

Table 108. Wockhardt Business Overview

Table 109. Wockhardt Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 110. Wockhardt Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 111. Wockhardt Recent Development

Table 112. Pfizer Company Details

Table 113. Pfizer Business Overview

Table 114. Pfizer Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 115. Pfizer Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 116. Pfizer Recent Development

Table 117. Merck Serono Company Details

Table 118. Merck Serono Business Overview

Table 119. Merck Serono Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 120. Merck Serono Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 121. Merck Serono Recent Development

Table 122. Roche Company Details

Table 123. Roche Business Overview

Table 124. Roche Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 125. Roche Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 126. Roche Recent Development

Table 127. Ferring Pharmaceuticals Company Details

Table 128. Ferring Pharmaceuticals Business Overview

Table 129. Ferring Pharmaceuticals Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 130. Ferring Pharmaceuticals Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 131. Ferring Pharmaceuticals Recent Development

Table 132. GeneScience Pharmaceuticals Company Details

Table 133. GeneScience Pharmaceuticals Business Overview

Table 134. GeneScience Pharmaceuticals Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 135. GeneScience Pharmaceuticals Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 136. GeneScience Pharmaceuticals Recent Development

Table 137. Ipsen Company Details

Table 138. Ipsen Business Overview

Table 139. Ipsen Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 140. Ipsen Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 141. Ipsen Recent Development

Table 142. LG Life Sciences Company Details

Table 143. LG Life Sciences Business Overview

Table 144. LG Life Sciences Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 145. LG Life Sciences Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 146. LG Life Sciences Recent Development

Table 147. Amoytop Company Details

Table 148. Amoytop Business Overview

Table 149. Amoytop Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 150. Amoytop Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 151. Amoytop Recent Development

Table 152. Anhui Anke Biotechnology Company Details

Table 153. Anhui Anke Biotechnology Business Overview

Table 154. Anhui Anke Biotechnology Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 155. Anhui Anke Biotechnology Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 156. Anhui Anke Biotechnology Recent Development

Table 157. Changchun High-tech Company Details

Table 158. Changchun High-tech Business Overview

Table 159. Changchun High-tech Self-administered Biologics for Metabolic & Endocrine Disorders Product

Table 160. Changchun High-tech Revenue in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025) & (US$ Million)

Table 161. Changchun High-tech Recent Development

Table 162. Research Programs/Design for This Report

Table 163. Key Data Information from Secondary Sources

Table 164. Key Data Information from Primary Sources

Table 165. Authors List of This Report

List of Figures

Figure 1. Self-administered Biologics for Metabolic & Endocrine Disorders Picture

Figure 2. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Type: 2024 VS 2031

Figure 4. Insulin Features

Figure 5. GLP-1 Receptor Agonists Features

Figure 6. rhGH Features

Figure 7. Other Features

Figure 8. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Comparison by Delivery Device (2020-2031) & (US$ Million)

Figure 9. Pre-filled syringe pens Features

Figure 10. Auto-injectors Features

Figure 11. Wearable infusion devices Features

Figure 12. Others Features

Figure 13. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size Comparison by Technological Characteristics (2020-2031) & (US$ Million)

Figure 14. Conventional Liquid Formulations Features

Figure 15. Sustained/Extended-release Biologics Features

Figure 16. Lyophilized Ready-to-use Formulations Features

Figure 17. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size by Application (2020-2031) & (US$ Million)

Figure 18. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Application: 2024 VS 2031

Figure 19. Hospital Case Studies

Figure 20. Home-based Self-administration Case Studies

Figure 21. Other Case Studies

Figure 22. Self-administered Biologics for Metabolic & Endocrine Disorders Report Years Considered

Figure 23. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 24. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 25. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Region: 2024 VS 2031

Figure 26. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Players in 2024

Figure 27. Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 28. The Top 10 and 5 Players Market Share by Self-administered Biologics for Metabolic & Endocrine Disorders Revenue in 2024

Figure 29. North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. North America Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Country (2020-2031)

Figure 31. United States Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Canada Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Europe Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Country (2020-2031)

Figure 35. Germany Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. France Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. U.K. Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Italy Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Russia Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Ireland Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Asia-Pacific Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Region (2020-2031)

Figure 43. China Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Japan Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. South Korea Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Southeast Asia Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. India Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Australia & New Zealand Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Latin America Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Country (2020-2031)

Figure 51. Mexico Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Brazil Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Middle East & Africa Self-administered Biologics for Metabolic & Endocrine Disorders Market Share by Country (2020-2031)

Figure 55. Israel Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. Saudi Arabia Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 57. UAE Self-administered Biologics for Metabolic & Endocrine Disorders Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 58. Novo Nordisk Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 59. Sanofi-Aventis Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 60. Eli Lilly Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 61. Tonghua Dongbao Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 62. United Laboratory Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 63. Biocon Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 64. GSK Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 66. Ganlee Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 67. Julphar Diabetes Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 68. Wockhardt Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 69. Pfizer Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 70. Merck Serono Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 71. Roche Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 72. Ferring Pharmaceuticals Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 73. GeneScience Pharmaceuticals Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 74. Ipsen Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 75. LG Life Sciences Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 76. Amoytop Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 77. Anhui Anke Biotechnology Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 78. Changchun High-tech Revenue Growth Rate in Self-administered Biologics for Metabolic & Endocrine Disorders Business (2020-2025)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-18O20079

Global Self-administered Biologics for Metabolic & Endocrine Disorders Market Research Report 2025

FEATURED COMPANIES

Self-administered Biologics for Metabolic & Endocrine Disorders Market Size

Self-administered Biologics for Metabolic & Endocrine Disorders Market

Scope of Self-administered Biologics for Metabolic & Endocrine Disorders Market Report

Chapter Outline

FAQ for this report

How fast is Self-administered Biologics for Metabolic & Endocrine Disorders Market growing?

What is the Self-administered Biologics for Metabolic & Endocrine Disorders Market size in 2031?

Who are the main players in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report?

What are the Application segmentation covered in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report?

What are the Type segmentation covered in the Self-administered Biologics for Metabolic & Endocrine Disorders Market report?

FEATURED COMPANIES